STS Intermacs 2019年度报告:器械与适应证的变迁
该报告基于STS Intermacs注册研究,分析2014年1月至2019年9月首次孤立植入连续流左心室辅助装置(LVAD)的患者。结果显示离心流LVAD已成为主流技术,目的地治疗(DT)成为最常见植入策略;全磁悬浮离心流(CF-FML)装置的整体生存和免于主要不良事件优于其他装置,但非随机注册研究比较需谨慎。
要点
- 离心流LVAD已取代轴流装置成为主流技术。
- DT成为最常见的LVAD植入策略。
- CF-FML装置生存和免于主要不良事件更优,但比较需谨慎。
核心结论
- 过去5年离心流LVAD成为主导技术,DT为最常见植入策略。
- CF-FML装置结局令人鼓舞,但非随机注册研究比较需谨慎。
研究设计与样本
- 基于STS Intermacs注册研究,纳入2014年1月至2019年9月首次孤立连续流LVAD植入患者。
- 比较轴流、混合悬浮离心流(CF-HL)和全磁悬浮离心流(CF-FML)装置的生存和免于主要不良事件。
主要发现
- 2014年植入2603例装置,其中轴流1824例(70.1%),DT 1213例(46.6%)。
- 截至2019年9月植入1752例装置,轴流仅37例(2.1%),DT 1230例(70.2%)。
- 2014至2018年共13,016例患者接受植入。
- 2017-2018年较2014-2016年患者更可能为Intermacs profile 1(17.1% vs 14.3%,P < .001)和术前临时机械循环支持(34.8% vs 29.3%,P < .001)。
- CF-FML装置的整体生存和免于主要不良事件更高。
临床怎么用
- 当前LVAD临床实践中应优先考虑离心流装置。
- DT已成为常见植入策略,需结合患者情况评估。
局限性
- 非随机注册研究,装置间比较需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The field of mechanical circulatory support has been impacted by the approval of new continuous-flow left ventricular assist devices (LVADs) and changes to the United States heart allocation system. METHODS: Primary isolated continuous-flow LVAD implants in The Society of Thoracic Surgeons Intermacs registry from January 2014 through September 2019 were evaluated. Survival and freedom from major adverse events were compared between axial-flow, centrifugal-flow with hybrid levitation (CF-HL), and centrifugal-flow with full magnetic levitation (CF-FML) devices. RESULTS: Of 2603 devices implanted in 2014, 1824 (70.1%) were axial flow and 1213 (46.6%) were destination therapy (DT); through September 2019, 1752 devices were implanted, but only 37 (2.1%) were axial flow and 1230 (70.2%) were DT. Implants were performed in 13,016 patients between 2014 and 2018. Patients receiving implants in 2017-2018 compared with 2014-2016 were more likely to be at Intermacs profile 1 (17.1% vs 14.3%, P < .001) and to have preimplant temporary mechanical circulatory support (34.8% vs 29.3%, P < .001). Overall survival and freedom from major adverse events were higher with CF-FML devices. In multivariable analysis of survival between CF-HL and CF-FML, device type was not a significant early hazard, but the use of CF-HL devices had a late hazard ratio for death of 3.01 (P < .001). CONCLUSIONS: Over the past 5 years, centrifugal-flow LVADs have become the dominant technology and DT the most common implant strategy. While outcomes with CF-FML devices are promising, comparisons with other devices from nonrandomized registry studies should be made with caution.
引用
- Teuteberg JJ, Cleveland JC, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann Thorac Surg. 2020. PMID: 32115073. doi:10.1016/j.athoracsur.2019.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。